Frankreich

2CRSi SA: Minutes of the Combined General Meeting of 31 August 2021.

ISIN, The Meeting, Policy, Mass meeting, PARC, Regulatory News Service, HAW, Mission statement, European, Board, Company secretary, Company, Celebrity board director, Forges, Annual general meeting, Combined, COO, Security (finance), Management
Jeudi, septembre 23, 2021 - 5:23pm

2CRSi SA: Minutes of the Combined General Meeting of 31 August 2021.

Key Points: 
  • 2CRSi SA: Minutes of the Combined General Meeting of 31 August 2021.
  • Strasbourg (France), 23 September 2021 - Shareholders in 2CRSi, a French manufacturer of high-performance, energy-efficient computer servers attended the Company's Combined General Meeting on 31 August 2021 at 11 rue Madeleine Reberioux, Parc des Forges - Le Terracotta, in Strasbourg.
  • Lastly, a representative for the statutory auditors presented their various reports to the General Meeting.
  • Presentations of the Company's FY 2020/2021 results and the votes on resolutions are available for consultation on its website: https://investors.2crsi.com/en/annual-general-meeting-08-31-2021/ .

DGAP-News: Abivax presents first-half 2021 financial results and operations update

ISIN, CEST, International Advisory and Monitoring Board, Population, Licensure, Program, EST, Methotrexate, Safety, Investment, EMA, DSMB, Research, JAK, MTX, Crohn's disease, Twitter, Bristol Myers Squibb, Hepatocellular carcinoma, Ulcerative colitis, MicroRNA, Maintenance, CHU, Headache, Operating cost, Chemokine, Clinical trial, Inflammatory Bowel Diseases, Probability, USD, Observation, Inflammation, FDA, Cancer, Nausea, Company, HCC, Scripps, Rheumatoid arthritis, CD, ITT, G&A, IBD, MD Anderson Cancer Center, ACR20, Cytokine, COVID-19, Patient, Trial of the century, Nivolumab, Degenerative disease, Film, Pharmaceutical industry, Animal, Birth control, Medical device, Poultry
Jeudi, septembre 23, 2021 - 5:23pm

2021 Research Tax Credit revenue amounts to EUR 1.6M as of June 30, 2021.

Key Points: 
  • 2021 Research Tax Credit revenue amounts to EUR 1.6M as of June 30, 2021.
  • Cash at the end of June 2021 was EUR 4.3M, compared to EUR 29.3M at the end of 2020, before taking into account the EUR 85M financing realized in July 2021.
  • In March 2021, Abivax announced it would be stopping the phase 2b/3 Covid-19 study (miR-AGE trial - ABX464-401) due to lack of efficacy.
  • Abivax would like to thank him for his contribution and wishes him all the best in his future endeavors.

ENERGISME: Verdantix study confirms the relevance of the Energisme solution and its added value for companies seeking to enhance their energy optimisation.

Software as a service, ISIN, SME, Sustainability, International trade, Enterprise, ESG, Regulatory News Service, Algorithm, Operational excellence, Research, Euronext Growth, Environment, Industry, Cryptocurrency, Renewable energy
Mercredi, septembre 22, 2021 - 6:57pm

ENERGISME: Verdantix study confirms the relevance of the Energisme solution and its added value for companies seeking to enhance their energy optimisation.

Key Points: 
  • ENERGISME: Verdantix study confirms the relevance of the Energisme solution and its added value for companies seeking to enhance their energy optimisation.
  • Energisme (FR0013399359/Ticker: ALNRG) announces the publication by independent research and consulting firm Verdantix of a report assessing the value proposition of Energisme's N'Gage platform for property managers and facility managers.
  • ENERGISME (ISIN code: FR0013399359/Ticker: ALNRG) has been listed on the Euronext Growth market since July 2020.
  • ENERGISME is eligible for SME personal equity plans and qualifies as a BPI Innovative Company.

Affluent Medical : Financial results for the first half of 2021 and main clinical update.

ESC, Man, Review, American College of Cardiology, Feedback, FCCP, Death, University, Icahn School of Medicine at Mount Sinai, Silver, Cotignola, Degenerative disease, University of Paris, Mitral valve, FAHA, Heart, Neuro, Group, Education, Committee, Journal, IFRS, Andreas, Cardiovascular disease, Urinary incontinence, EAU, Professor, Company, FESC, Health policy, BJU International, Kalio, Mehran, SAIME, NYHA, The Journal of Urology, Surgeon, COVID-19, Patient, FACC, FACP, American College, Ethics, Adrenal insufficiency, Nature Reviews Urology, Trial of the century, Mount Sinai Hospital, IPO, European Urology, Artus, Animal, Security (finance), Medical device, Pharmaceutical industry, Medicine
Mercredi, septembre 22, 2021 - 6:56pm

During the first half of 2021, purchases consumed fell by 158 thousand compared to the first half of 2020.

Key Points: 
  • During the first half of 2021, purchases consumed fell by 158 thousand compared to the first half of 2020.
  • On 9 June 2021, Affluent Medical announced the success of its IPO on the regulated market of Euronext Paris.
  • Starting in 2018 he broadened his field of expertise by engaging in various entrepreneurial projects before joining Affluent Medical.
  • Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas.